Related Experiment Videos
[The effect of massive intravenous doses of furosemide in chronic kidney failure]
Orvosi Hetilap
|May 27, 1973
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pathologic assessment of response to chemotherapy in colorectal cancer liver metastases after hepatic resection: which method to use?
Pathology oncology research : POR·2014
The comparison of thrombocytosis and platelet-lymphocyte ratio as potential prognostic markers in colorectal cancer.
Thrombosis and haemostasis·2013
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
European journal of cancer (Oxford, England : 1990)·2013
Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
Pathology oncology research : POR·2013
Prediction of cervical infiltration in Stage II endometrial cancer by different preoperative evaluation techniques (D&C, US, CT, MRI).
European journal of gynaecological oncology·2003
[Orthognathic surgery for the treatment of obstructive sleep apnea].
Orvosi hetilap·2026
[On the way to tobacco- and nicotine-free healthcare institutions].
Orvosi hetilap·2026
[Disordered eating behaviors and eating disorders among athletes II.]
Orvosi hetilap·2026
[Acute psychological stress and endometriosis-related pain].
Orvosi hetilap·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026